TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1100294
Drug: Lirutrin (measles‐mumps‐rubella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lirutrin (measles‐mumps‐rubella live, attenuated virus vaccine)
Study: 25394681
Drug: BCAA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA and zinc-enriched supplementation (6,400 mg/day BCAAs and 10 mg/day zinc)
Study: 16443054
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1%
Study: 11845949
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel 0.025%
Study: 8988956
Drug: Pindolol (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5.0 mg b.i.d. or 2.5 mg t.i.d.)
Study: 23566058
Drug: Oligonol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligonol (100 mg)
Study: 17127546
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg IV cocaine
Study: 17127546
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg IV cocaine
Study: 12824826
Drug: Laser photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photocoagulation therapy
Study: 2343728
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg
Study: 2938518
Drug: 0.14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.14 mg/kg of midazolam (midazolam hydrochloride 5 mg/ml)
Study: 2938518
Drug: 0.29 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.29 mg/kg diazepam (Valium 5 mg/ml)
Study: 18502245
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for depression
Study: 28810355
Drug: Cognitive-affective preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-affective preparation session
Study: 25270545
Drug: Fixed-volume implant
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-volume implant in 1 breast and an adjustable-volume implant in the other
Study: 25270545
Drug: Two fixed-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two fixed-volume implants of different sizes
Study: 22920839
Drug: Sling exercise
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling exercise therapy (ST)
Study: 30888702
Drug: Anti-RPA194 antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-RPA194 antibodies
Study: 8609324
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone
Study: 7734467
Drug: Continuity by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuity by having the intake therapist become the treatment therapist
Study: 2659955
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg i.m. every 3 weeks for 12 months)
Study: 17083882
Drug: Topical calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcineurin inhibitors (pimecrolimus and tacrolimus)
Study: 17083882
Drug: FDA black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA black box warning on topical calcineurin inhibitors
Study: 25992279
Drug: iloprost 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: iloprost 5.0 µg
Study: 25992279
Drug: iloprost 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: iloprost 2.5 µg or 5.0 µg in iPAH subset
Study: 24617227
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment of diabetes (Control group)
Study: 12624551
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (20 ml 0.375% bupivacaine through L(3‐4) inter‐space)
Study: 9509181
Drug: Chloroquine/Chlorpheniramine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine/Chlorpheniramine combination
Study: 28729021
Drug: Ceritinib 750
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 750 mg fasted
Study: 19325998
Drug: Cold-water-spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-water-spray
Study: 16295047
Drug: lercanidipine 10-20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 10-20 mg/day
Study: 16295047
Drug: ramipril 5-10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5-10 mg/day
Study: 11408852
Drug: Amoxicillin, 500
Normalized name: Amoxicillin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 500 mg, three times daily for 7 days
Study: 3654947
Drug: SV vaccine
Normalized name: RSV VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SV vaccine (one dose)
Study: 3654947
Drug: SV vaccine
Normalized name: RSV VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SV vaccine (two doses)
Study: 3654947
Drug: WV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WV vaccine (two doses)
Study: 3654947
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (one or two doses)
Study: 3654947
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose (one month after first dose)
Study: 25314004
Drug: Calcium-collagen chelate
Normalized name: calcium amino acid chelate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-collagen chelate (CC) dietary supplement (5g containing 500mg of elemental calcium and 200IU vitamin D)
Study: 18474769
Drug: Low-vision rehabilitation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vision rehabilitation program including low-vision examination, counseling, prescription and provision of low-vision devices, and 6 weekly sessions with a low-vision therapist.
Study: 10668769
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg orally three times a day
Study: 7903218
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg
Study: 8095894
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg + Prazosin 1 mg
Study: 799569
Drug: Prazosin 1
Normalized name: prazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 1 mg
Study: 2137076
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs
Study: 3090959
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1,500,000 U in 30 mn)
Study: 3090959
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin therapy
Study: 8044944
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase
Study: 30996007
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks for up to 24 months
Study: 23031804
Drug: TEASAP (Treatment-Emergent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEASAP (Treatment-Emergent Activation and Suicidality Assessment Profile)
Study: 15474758
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg buccal estradiol
Study: 15474758
Drug: 0.05, 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05, 0.1, 0.2 mg buccal estradiol
Study: 6387888
Drug: Metoprolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50-100 mg twice daily)
Study: 16296711
Drug: Diltiazem (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-120 mg three times daily)
Study: 9421122
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus lymecycline 300 mg b.i.d (Group B)
Study: 8050697
Drug: Bismuth 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth 240 mg
Study: 8050697
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg + Bismuth 240 mg
Study: 30234149
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg twice daily)
Study: 4413081
Drug: Prednisone, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 3 mg/kg per day for 10 days
Study: 4413081
Drug: Sodium salicylate,
Normalized name: Sodium Salicylate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate, 100 mg/kg per day for 10 days
Study: 31765110
Drug: lisdexamfetamine 20
Normalized name: lisdexamfetamine 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisdexamfetamine 20 mg on Day 1, then 20 mg/d (Days 4-8), 50 mg/d (Days 9-13), 70 mg/d (Days 14-18)
Study: 23465055
Drug: fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine 4 mg once daily for the first 4 weeks, with an option to increase to 8 mg once daily for the remaining 8 weeks
Study: 23465055
Drug: fesoterodine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine treatment
Study: 21430035
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent bolus 2.5 mL every 15 minutes (2.5/15)
Study: 19301089
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg/week), calcium (1,000 mg/day), and vitamin D (400 IU/day) for 12 months
Study: 19301089
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg/day) and vitamin D (400 IU/day)
Study: 17049060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintenance CsA dose)
Study: 23348843
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate
Study: 9701531
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg
Study: 9701531
Drug: Rabeprazole 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 40 mg
Study: 9322642
Drug: Cefetamet-pivoxil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet-pivoxil (2 gm single oral dose)
Study: 8418401
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy plus optimal medical treatment (aspirin) (surgical group; n=211)
Study: 23910233
Drug: Treatment stoppage
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment stoppage due to side effects
Study: 22089885
Drug: Standard Multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Multidisciplinary Medical Therapy (MT)
Study: 11417777
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch
Study: 27994503
Drug: Far-Infrared Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Far-Infrared Radiation (FIR) therapy applied for 40 minutes during each hemodialysis session, three times per week for six months.
Study: 21689141
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks
Study: 21689141
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks
Study: 17703640
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg daily
Study: 15901045
Drug: Coated tablet
Normalized name: COATED TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablet formulation B (5 mg finasteride)
Study: 10856145
Drug: Zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast 20 mg twice daily
Study: 1641497
Drug: Adjunctive imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive imipramine added to ongoing medication regimen of fluphenazine decanoate and benztropine
Study: 2371372
Drug: Adjunctive imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive imipramine
Study: 25256660
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg via subcutaneous injection into the thigh
Study: 17916813
Drug: Standard ambulance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ambulance transfer and treatment
Study: 12143944
Drug: Oral nitrates
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nitrates (n=504)
Study: 12143944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral and transdermal nitrates (n=60)
Study: 9989541
Drug: DASH combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH combination diet
Study: 7476284
Drug: Insulin/glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/glucose infusion at 0.025/2.0 U/kg.h and mg/kg.min
Study: 7476284
Drug: Insulin/glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/glucose infusion at 0.050/3.5 U/kg.h and mg/kg.min
Study: 7476284
Drug: Insulin/glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/glucose infusion at 0.100/6.0 U/kg.h and mg/kg.min
Study: 7476284
Drug: Insulin/glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/glucose infusion at 0.200/8.0 U/kg.h and mg/kg.min
Study: 2179134
Drug: Cefotaxime at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime at a dosage of 2 x 3 g/day for ten days
Study: 10722441
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G
Study: 450561
Drug: Oral safflower
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral safflower oil (1 gm/kg/day)
Study: 20142306
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg dDAVP bolus (over 1 min)
Study: 19261236
Drug: Alcohol (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (moderate dose)
Study: 12198057
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg IV
Study: 16428536
Drug: Methylprednisolone 125
Normalized name: methylprednisolone 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 125 mg IV
Study: 8159194
Drug: Imipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine at a dose of 50 mg nightly
Study: 8159194
Drug: Clonidine at
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine at a dose of 0.1 mg twice daily
Study: 1629885
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg/day)
Study: 17015043
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation coupled with the use of an inhaled bronchodilator
Study: 9207721
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with encapsulated short ragweed extract
Study: 3532799
Drug: Gestrinone 5
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 5 mg capsules twice weekly (Group A)
Study: 3532799
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg capsules three times weekly (Group B)
Study: 3532799
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg vaginal tablets three times weekly (Group C)
Study: 3532799
Drug: Gestrinone treatment
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone treatment overall
Study: 31758329
Drug: Continuous regional
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regional arterial infusion (CRAI) of nafamostat mesilate (NM)
Study: 31758329
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration (IV) of nafamostat mesilate (NM)
Study: 26456487
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVT) - 3 monthly injections followed by PRN treatment
Study: 20598985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Valsartan and Captopril
Study: 7782055
Drug: Follicle-stimulating hormone
Normalized name: Follicle-stimulating hormone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follicle-stimulating hormone (FSH)
Study: 3106101
Drug: Buserelin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (0.3 ml twice a day subcutaneously for 14 days) followed by FSH
Study: 16984065
Drug: Empirical antisecretory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antisecretory therapy followed by Helicobacter pylori testing if symptoms improved
Study: 16984065
Drug: Empirical antisecretory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antisecretory therapy
Study: 1286496
Drug: Flumazenil (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.7 mg, 7 ml)
Study: 1286496
Drug: Placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9 ml)
Study: 27742871
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 µg)
Study: 26922022
Drug: Ipratropium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (80 µg)
Study: 26922022
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (salbutamol and ipratropium)
Study: 11241803
Drug: Indomethacin (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (i.v. 0.2 mg/kg b.w.)
Study: 11241803
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (placebo, 20 mL)
Study: 9647934
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy in hypogonadal men
Study: 9647934
Drug: No testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No testosterone administration in eugonadal men
Study: 12068251
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg ethanol
Study: 31068229
Drug: Cream of
Normalized name: Nubasics Soup Cream of Chicken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream of Rice (CR)
Study: 28454829
Drug: Culprit lesion
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culprit lesion treatment-only strategy
Study: 24267005
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (100 IU vitamin D, 500 mg calcium per 200 mL)
Study: 24267005
Drug: Fortified orange
Normalized name: Nutritional Supplement Oral Liquid [FORTIFIED ORANGE JUICE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified orange juice (100 IU vitamin D, 500 mg calcium per 200 mL)
Study: 24267005
Drug: Supplement (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (200 IU vitamin D, 500 mg calcium)
Study: 17954800
Drug: Chlorhexidine-based solution
Normalized name: chlorhexidine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-based solution (0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzylic alcohol)
Study: 1927943
Drug: Intermittent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent use of transdermal nitroglycerin (10 mg/24 hours)
Study: 1927943
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of transdermal nitroglycerin (10 mg/24 hours)
Study: 6356740
Drug: Gangliosides (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gangliosides (20 mg daily i.m.)
Study: 29713850
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual
Study: 30593607
Drug: MEDI4166 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4166 50 mg
Study: 30593607
Drug: MEDI4166 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4166 200 mg
Study: 30593607
Drug: MEDI4166 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4166 400 mg
Study: 26808856
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg·kg body mass
Study: 19699335
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day for 2 days
Study: 2476978
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid treatment
Study: 26242578
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg daily)
Study: 21658524
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (wait-list control)
Study: 15329302
Drug: Neuropsychological assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropsychological assessment prior to smoking cessation treatment (including VSWM and WCST)
Study: 11748103
Drug: Acetylcholine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine infusion in Hyperthyroidism (H)
Study: 11748103
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion in Hyperthyroidism (H)
Study: 9662077
Drug: Duodenal lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal lipid (Intralipid 20%) infusion for 45 minutes